Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVE: Dostarlimab with or without Bevacizumab versus non‑platinum chemotherapy in recurrent gynecological clear cell carcinoma
jRCT2031240642Phase 2Active, not recruiting
- Sponsor
- Severance Hospital, Yonsei University Health System
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial of dostarlimab in clear cell ovarian cancer (3 arms), sponsored by Severance Hospital, Yonsei University Health System. Primary endpoint: Progression Free Survival (PFS). Started Jan 2025; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
clear cell ovarian cancer
Beyond the preview
Go deeper on jRCT2031240642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240642.